1. Home
  2. GALT vs QNTM Comparison

GALT vs QNTM Comparison

Compare GALT & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GALT
  • QNTM
  • Stock Information
  • Founded
  • GALT 2000
  • QNTM 1998
  • Country
  • GALT United States
  • QNTM Canada
  • Employees
  • GALT N/A
  • QNTM N/A
  • Industry
  • GALT Biotechnology: Pharmaceutical Preparations
  • QNTM
  • Sector
  • GALT Health Care
  • QNTM
  • Exchange
  • GALT Nasdaq
  • QNTM NYSE
  • Market Cap
  • GALT 83.5M
  • QNTM 69.3M
  • IPO Year
  • GALT N/A
  • QNTM N/A
  • Fundamental
  • Price
  • GALT $2.52
  • QNTM $18.56
  • Analyst Decision
  • GALT Buy
  • QNTM
  • Analyst Count
  • GALT 2
  • QNTM 0
  • Target Price
  • GALT $6.00
  • QNTM N/A
  • AVG Volume (30 Days)
  • GALT 1.5M
  • QNTM 408.2K
  • Earning Date
  • GALT 08-12-2025
  • QNTM 08-13-2025
  • Dividend Yield
  • GALT N/A
  • QNTM N/A
  • EPS Growth
  • GALT N/A
  • QNTM N/A
  • EPS
  • GALT N/A
  • QNTM N/A
  • Revenue
  • GALT N/A
  • QNTM N/A
  • Revenue This Year
  • GALT N/A
  • QNTM N/A
  • Revenue Next Year
  • GALT N/A
  • QNTM N/A
  • P/E Ratio
  • GALT N/A
  • QNTM N/A
  • Revenue Growth
  • GALT N/A
  • QNTM N/A
  • 52 Week Low
  • GALT $0.73
  • QNTM $2.70
  • 52 Week High
  • GALT $3.90
  • QNTM $38.25
  • Technical
  • Relative Strength Index (RSI)
  • GALT 63.30
  • QNTM 50.64
  • Support Level
  • GALT $2.07
  • QNTM $15.88
  • Resistance Level
  • GALT $2.36
  • QNTM $24.32
  • Average True Range (ATR)
  • GALT 0.27
  • QNTM 3.58
  • MACD
  • GALT -0.01
  • QNTM -1.07
  • Stochastic Oscillator
  • GALT 61.64
  • QNTM 13.59

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

About QNTM QUANTUM BIOPHARMA LTD

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

Share on Social Networks: